Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line
about
P1343
Overcoming multidrug resistance via photodestruction of ABCG2-rich extracellular vesicles sequestering photosensitive chemotherapeuticsStructure and function of ABCG2-rich extracellular vesicles mediating multidrug resistanceAcquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDsDevelopment of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalphaMicrofluidic cell isolation technology for drug testing of single tumor cells and their clusters.Enhancement of chemotherapy by manipulation of tumour pH.Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imagingFolate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis.Proteomic analysis of prodigiosin-induced apoptosis in a breast cancer mitoxantrone-resistant (MCF-7 MR) cell line.Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in Caco-2 cells.Causes and effects of heterogeneous perfusion in tumorsCharacterization of breast cancers and therapy response by MRS and quantitative gene expression profiling in the choline pathway.99mTc glucarate high-resolution imaging of drug sensitive and drug resistant human breast cancer xenografts in SCID mice.Imaging recognition of inhibition of multidrug resistance in human breast cancer xenografts using 99mTc-labeled sestamibi and tetrofosmin.Imaging recognition of multidrug resistance in human breast tumors using 99mTc-labeled monocationic agents and a high-resolution stationary SPECT system.The role of drug efflux pumps in acute myeloid leukemia.APC selectively mediates response to chemotherapeutic agents in breast cancer.Multidrug resistance proteins in rheumatoid arthritis, role in disease-modifying antirheumatic drug efficacy and inflammatory processes: an overview.Potential Therapeutic Effect of Natural Killer Cells on Doxorubicin-Resistant Breast Cancer Cells In Vitro.Drug Transporters and Na+/H+ Exchange Regulatory Factor PSD-95/Drosophila Discs Large/ZO-1 ProteinsABCG2 expression, function, and promoter methylation in human multiple myelomaChanges in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells.Quantitative determination of mdr1 gene expression in leukaemic cells from patients with acute leukaemia.The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2).Cucurbitacin D induces cell cycle arrest and apoptosis by inhibiting STAT3 and NF-κB signaling in doxorubicin-resistant human breast carcinoma (MCF7/ADR) cellsTumor acidity, chemoresistance and proton pump inhibitors.ABCG2: determining its relevance in clinical drug resistance.Psorospermin structural requirements for P-glycoprotein resistance reversal.Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells.BCRP expression does not result in resistance to STX140 in vivo, despite the increased expression of BCRP in A2780 cells in vitro after long-term STX140 exposure.Priming cancer cells for drug resistance: role of the fibroblast niche.Amplification of 4q21-q22 and the MXR gene in independently derived mitoxantrone-resistant cell lines.Mitoxantrone, More than Just Another Topoisomerase II Poison.Preferential Langerhans cell differentiation from CD34(+) precursors upon introduction of ABCG2 (BCRP).Knockdown of TSP50 inhibits cell proliferation and induces apoptosis in P19 cells.Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype.Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib.Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates.Targeting an extracellular epitope of the human multidrug resistance protein 1 (MRP1) in malignant cells with a novel recombinant single chain Fv antibody.Cellular models for multiple drug resistance in cancer.
P2860
Q27304425-F664C73B-CC42-497A-B3D0-D551382F8314Q27437985-4153BDA0-70B4-46F4-A9DC-7C20B3CEEBA3Q28394186-DD2F54CE-8C97-47E2-ACC2-F97D2159CC0AQ28394197-EFABD3FE-5C5A-4FAA-98D7-E7DC8BEC924CQ30364122-1884DE09-8E57-49AA-892E-D935DA528DFAQ30578111-936E10C2-2393-4805-B4AB-47E2C79B3EB7Q30606326-B33091C8-BC41-47F0-8441-6B5CD8F7C0E9Q33200355-F749D5F1-1EF1-45B5-8A84-BE3B8B5DAA01Q33240858-367043DE-FE70-430D-BEE0-D2FD5D9CBFE2Q33351355-72A96F3F-ABFE-4B1F-8298-D362363032B2Q33997836-637FE7D2-DC95-4152-8361-24DEAA0E9171Q34035237-A3A0D773-6563-4E1C-9610-839D87A8223BQ34157246-076D8E03-DF74-4D03-9F01-08779516F0A9Q34450507-911C09B6-69A0-4448-B41C-483B52774C03Q34711648-DE895629-1305-47FF-B603-D209BA1A4C52Q34769834-1AAA77B6-DB84-4163-9D7B-257E19808EFBQ35655334-11EEAEA0-D224-4870-8601-1A34C532137CQ35744255-7677F3D4-0A3D-4375-9DAD-ECAA68982F9EQ35752181-1F6A14AA-BE0C-4D4F-B9D6-C0F214C3C77DQ35795744-6AABD277-0603-4A7B-8C3C-788107EECBD1Q35848835-895CF57D-3818-49CC-BA11-429C1354AEB7Q35977902-B151B081-6260-4AA2-BA1A-A08D36EDEC6AQ35994137-6D642EB4-F9C8-4B42-B6A4-95C32A660CF2Q36052743-FCB50A4D-3287-4782-8936-6F8DD2F6B258Q36109261-A1566859-9095-4F7C-A912-08B98C3D231EQ36429624-BC391D34-AC60-4357-B10A-F4612451AB6FQ36745478-196BADFE-EEFE-49BD-9AAF-B6F7F2978D51Q36982551-BAC6C0DD-66D7-4D65-AADA-4163D2E37FF2Q37093674-01812530-0D00-45A4-A60A-DD1DECB1A456Q37135243-E4F24F0F-E761-4D72-B572-060347379D09Q38232067-95BFF4F4-589C-4A17-BB3B-89F585A678A4Q38498733-357BA75E-0A1F-471D-A09D-587BE3F89D37Q38569206-AEA52FDA-5730-430A-9314-DD05CF7F2C2BQ39569136-613F2195-A844-400F-A966-3344939BCEEAQ39630315-53FD3D2E-1B0E-45C2-9A75-EAFFC82176BBQ39645483-744B76C2-6C52-4D09-8C2E-3DF446C43073Q39874489-943DC938-69A4-4FAA-A0FA-5298ED7D0F50Q40292892-446A94F3-2E39-4AD0-B4EE-DD5B018679D5Q40550562-7818EACF-0B15-44F2-B0A9-CC92622606B5Q40708934-9282D859-723C-444A-A130-C1EA8317EB8B
P2860
Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Different mechanisms of decrea ...... human breast cancer cell line
@ast
Different mechanisms of decrea ...... human breast cancer cell line
@en
type
label
Different mechanisms of decrea ...... human breast cancer cell line
@ast
Different mechanisms of decrea ...... human breast cancer cell line
@en
prefLabel
Different mechanisms of decrea ...... human breast cancer cell line
@ast
Different mechanisms of decrea ...... human breast cancer cell line
@en
P2093
P2860
P356
P1476
Different mechanisms of decrea ...... human breast cancer cell line
@en
P2093
C W Taylor
F H Thompson
M C Gleason
P R Parrish
W S Dalton
W T Bellamy
P2860
P2888
P304
P356
10.1038/BJC.1991.202
P407
P4510
P577
1991-06-01T00:00:00Z
P5875
P6179
1016256084